Age and comorbidities deeply impact on clinical outcome of patients with myelodysplastic syndromes

Leukemia Research

Volumn 39, Issue 8, 2015, Pages 846-852

  Balleari, E ^a   Salvetti, C ^a   Del Corso, L ^a   Filiberti, R ^a   Bacigalupo, A ^a   Bellodi, A ^a   Beltrami, G ^a   Bergamaschi, M ^a   Berisso, G ^b   Calzamiglia, T ^c   Carella, A M ^a   Cavalleri, M ^d   Da Col, A ^a   Favorini, S ^a   Forni, G L ^e   Goretti, R ^f   Miglino, M ^a   Mitscheuning, L ^a   Molinari, E ^a   Racchi, O ^g   Scudeletti, M ^d   Tassara, R ^h   Gobbi, M ^a   Lemoli, R ^a   Clavio, M ^a   more..

^a UNIVERSITY OF GENOA   (Italy)

^b UO Internal Medicine ASL 5   (Italy)

^c UO Internal Medicine ASL 1   (Italy)

^d UO Internal Medicine ASL 4   (Italy)

^e UO Hematology EO Galliera   (Italy)

^f UO Internal Medicine ASL 2   (Italy)

^g UO Hemato Oncology ASL 3   (Italy)

^h ASL 2   (Italy)

Author keywords

Comorbidity; Elderly; Myelodysplastic syndromes; Prognosis

Indexed keywords

ACUTE MYELOBLASTIC LEUKEMIA; ADULT; AGE; AGED; ARTICLE; CANCER GROWTH; CANCER MORTALITY; CANCER PROGNOSIS; CANCER SURVIVAL; CEREBROVASCULAR DISEASE; COHORT ANALYSIS; COMORBIDITY; COMORBIDITY ASSESSMENT; DIABETES MELLITUS; DISEASE SEVERITY; ENDOCRINE DISEASE; FEMALE; GASTROINTESTINAL DISEASE; HEART DISEASE; HEMATOPOIETIC CELL TRANSPLANTATION SPECIFIC COMORBIDITY INDEX; HUMAN; INTERNATIONAL PROGNOSTIC SCORING SYSTEM; KIDNEY DISEASE; LIVER DISEASE; LUNG DISEASE; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; MYELODYSPLASTIC SYNDROME; MYELODYSPLASTIC SYNDROME SPECIFIC COMORBIDITY INDEX; OBESITY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PATIENT RISK; PREVALENCE; PRIORITY JOURNAL; REFRACTORY ANEMIA; REFRACTORY CYTOPENIA WITH MULTILINEAGE DYSPLASIA; RETROSPECTIVE STUDY; RHEUMATIC DISEASE; RISK ASSESSMENT; SURVIVAL PREDICTION; MIDDLE AGED; MORTALITY; MYELODYSPLASTIC SYNDROMES; PROGNOSIS; SURVIVAL; VERY ELDERLY;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; COMORBIDITY; FEMALE; HUMANS; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; PREVALENCE; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS;

EID: 84937524680     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2015.05.007     Document Type: Article

References (30)

1. Tefferi A., Vardiman J.W. Myelodysplastic syndromes. N. Engl. J. Med. 2009, 361:1872-1885. 10.1056/NEJMra0902908.
2. Cazzola M., Malcovati L. Myelodysplastic syndromes - coping with ineffective hematopoiesis. N. Engl. J. Med. 2005, 352:536-538.
3. Greenberg P., Cox C., LeBeau M.M., Fenaux P., Morel P., Sanz G., et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997, 89:2079-2088.
4. Greenberg P.L., Tuechler H., Schanz J., Sanz G., Garcia-Manero G., Solé F., et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood 2012, 120:2454-2465.
5. Voso M.T., Fenu S., Latagliata R., Buccisano F., Piciocchi A., Aloe-Spiriti M.A., et al. Revised International Prognostic Scoring System (IPSS) predicts survival and leukemic evolution of myelodysplastic syndromes significantly better than IPSS and WHO Prognostic Scoring System: validation by the Gruppo Romano Mielodisplasie Italian Regional Database. J. Clin. Oncol. 2013, 31:2671-2677. 10.1200/JCO.2012.48.0764.
6. Greenberg P.L., Attar E., Bennett J.M., Bloomfield C.D., Borate U., De Castro C.M., et al. Myelodysplastic syndromes: clinical practice guidelines in oncology. J. Natl. Compr. Cancer Netw. 2013, 11:838-874.
7. Malcovati L., Hellström-Lindberg E., Bowen D., Adès L., Cermak J., Del Cañizo C., et al. Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet. Blood 2013, 122:2943-2964. 10.1182/blood-2013-03-492884.
8. Kantarjian H., O'Brien S., Ravandi F., Cortes J., Shan J., Bennett J.M., et al. Proposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original International Prognostic Scoring System. Cancer 2008, 113:1351-1361. 10.1002/cncr.23697.
9. Rollison D.E., Howlader N., Smith M.T., Strom S.S., Merritt W.D., Ries L.A., et al. Epidemiology of myelodysplastic syndromes and chronic myeloproliferative disorders in the United States, 2001-2004, using data from the NAACCR and SEER programs. Blood 2008, 112:45-52. 10.1182/blood-2008-01-134858.
10. Ma X., Does M., Raza A., Mayne S.T. Myelodysplastic syndromes. Incidence and survival in the United States. Cancer 2007, 109:1536-1542.
11. Alessandrino E.P., Della Porta M.G., Bacigalupo A., Van Lint M.T., Falda M., Onida F., et al. WHO classification and WPSS predict post-transplantation outcome in patients with myelodysplastic syndrome: a study from the Gruppo Italiano Trapianto di Midollo Osseo (GITMO). Blood 2008, 112:895-902. 10.1182/blood-2008-03-143735.
12. Repetto L., Fratino L., Audisio R.A., Venturino A., Gianni W., Vercelli M., et al. Comprehensive geriatric assessment adds information to Eastern Cooperative Oncology Group performance status in elderly cancer patients: an Italian Group for Geriatric Oncology Study. J. Clin. Oncol. 2002, 20:494-502.
13. Wang R., Gross C.P., Halene S., Ma X. Comorbidities and survival in a large cohort of patients with newly diagnosed myelodysplastic syndromes. Leuk. Res. 2009, 33:1594-1598. 10.1016/j.leukres.2009.02.005.
14. Zipperer E., Pelz D., Nachtkamp K., Kuendgen A., Strupp C., Gattermann N., et al. The hematopoietic stem cell transplantation comorbidity index is of prognostic relevance for patients with myelodysplastic syndrome. Haematologica 2009, 94:729-732. 10.3324/haematol.2008.002063.
15. Sperr W.R., Wimazal F., Kundi M., Baumgartner C., Nösslinger T., Makrai A., et al. Comorbidity as prognostic variable in MDS: comparative evaluation of the HCTCI and CCI in a core dataset of 419 patients of the Austrian MDS Study Group. Ann. Oncol. 2010, 21:114-119. 10.1093/annonc/mdp258.
16. Della Porta M.G., Malcovati L., Strupp C., Ambaglio I., Kuendgen A., Zipperer E., et al. Risk stratification based on both disease status and extra-hematologic comorbidities in patients with myelodysplastic syndrome. Haematologica 2011, 96:441-449. 10.3324/haematol.2010.033506.
17. Breccia M., Federico V., Latagliata R., Mercanti C., D'Elia G.M., Cannella L., et al. Evaluation of comorbidities at diagnosis predicts outcome in myelodysplastic syndrome patients. Leuk. Res. 2011, 35:159-162. 10.1016/j.leukres.2010.06.005.
18. Naqvi K., Garcia-Manero G., Sardesai S., Oh J., Vigil C.E., Pierce S., et al. Association of comorbidities with overall survival in myelodysplastic syndrome: development of a prognostic model. J. Clin. Oncol. 2011, 29:2240-2246. 10.1200/JCO.2010.31.3353.
19. Zippeter E., Tanha N., Strupp C., Kündgen A., Nachtkamp K., Neukirchen J., et al. The myelodysplastic syndrome-comorbidity index provides additional prognostic information on patients stratified according to the revised international prognostic scoring system. Haematologica 2014, 99:31-32. 10.3324/haematol.2013.101055.
20. Sorror M.L., Maris M.B., Storb R., Baron F., Sandmaier B.M., Maloney D.G., et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood 2005, 106:2912-2919.
21. Charlson M.E., Pompei P., Ales K.L., Mac Kenzie C.R. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J. Chronic Dis. 1987, 40:373-383.
22. Fine J.P., Gray R.J. A proportional hazards model for the subdistribution of a competing risk. J. Am. Stat. Assoc. 1999, 94:496-509.
23. Sperr W.R., Kundi M., Wimazal F., Nösslinger T., Schönmetzler-Makrai A., Stauder R., et al. Proposed score for survival of patients with myelodysplastic syndromes. Eur. J. Clin. Investig. 2013, 43:1120-1126. 10.1111/eci.12149.
24. Stauder R., Nosslinger T., Pfeilstocker M., Sperr W.R., Wimazal F., Krieger O., et al. Impact of age and comorbidity in myelodysplastic syndromes. J. Natl. Compr. Cancer Netw. 2008, 6:927-934.
25. Nosslinger T., Tuchler H., Germing U., Sperr W.R., Krieger O., Haase D., et al. Prognostic impact of age and gender in 897 untreated patients with primary myelodysplastic syndromes. Ann. Oncol. 2010, 21:120-125. 10.1093/annonc/mdp264.
26. Bammer C., Sperr W.R., Kemmler G., Wimazal F., Nösslinger T., Schönmetzler A., et al. Clustering of comorbidities is related to age and sex and impacts clinical outcome in myelodysplastic syndromes. J. Geriatr. Oncol. 2014, 5:299-306. 10.1016/j.jgo.2014.02.002.
27. Piccirillo J.F., Costas I., Claybour P., Borah A.J., Grove L., Jeffe D. The measurement of comorbidity by cancer registries. J. Regist. Manag. 2003, 30:8-14.
28. Della Porta M.G., Ambaglio I., Ubezio M., Travaglino E., Pascutto C., Malcovati L. Clinical evaluation of extra-hematologic comorbidity in Myelodysplastic syndromes: ready-to-wear versus made-to-measure tool. Haematologica 2012, 97:631-632. 10.3324/haematol.2011.057323.
29. Malcovati L., Della Porta M.G., Strupp C., Ambaglio I., Kuendgen A., Nachtkamp K., et al. Impact of the degree of anemia on the outcome of patients with myelodysplastic syndrome and its integration into the WHO classification-based Prognostic Scoring System (WPSS). Haematologica 2011, 96:1433-1440. 10.3324/haematol.2011.044602.
30. Malcovati L., Porta M.G., Pascutto C., Invernizzi R., Boni M., Travaglino E., et al. Prognostic factors and life expectancy expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making. J. Clin. Oncol. 2005, 23:7594-7603. 10.1200/JCO.2005.01.7038.